Publications by authors named "N Romero"
A new antioxidant lipid (AL) was synthesized from rainbow trout () belly oil and cold-pressed maqui (CPM) ( (Mol.) Stuntz) seed oil via enzymatic interesterification using in supercritical CO medium. A Box-Behnken design with 15 experiments was employed, with the independent variables being the following: belly oil/CPM oil ratio (10/90, 50/50, and 90/10, /), supercritical CO temperature (40.
View Article and Find Full Text PDFNeuromuscular disorders (NMD) with neonatal or early infantile onset are usually severe and differ in symptoms, complications, and treatment options. The establishment of a diagnosis relies on the combination of clinical examination, morphological analyses of muscle biopsies, and genetic investigations. Here, we re-evaluated and classified a unique collection of 535 muscle biopsies from NMD infants aged 0-6 months examined over a period of 52 years.
View Article and Find Full Text PDFArticle Synopsis
- * Four groups of male C57BL/6 mice were supplemented with either control diet or HFD, with either sunflower oil or maqui oil, over a 12-week period.
- * Results showed that MO supplementation led to significant reductions in visceral fat, liver fat infiltration, and certain liver enzyme levels, indicating its potential to combat fatty liver disease and suggesting further research for human health applications.
-related myopathies: clinical, myopathological and genotypic spectrum in a multicentre French cohort.
J Neurol Neurosurg Psychiatry
October 2024
Background: Myosin heavy chain 7 ()-related myopathies (-RMs) are a group of muscle disorders linked to pathogenic variants in the gene, encoding the slow/beta-cardiac myosin heavy chain, which is highly expressed in skeletal muscle and heart. The phenotype is heterogeneous including distal, predominantly axial or scapuloperoneal myopathies with variable cardiac involvement.
Methods: We retrospectively analysed the clinical, muscle MRI, genetic and myopathological features of 57 patients.
Article Synopsis
- Dexmedetomidine is used longer than its recommended duration in critically ill adults, leading to concerns about potential withdrawal symptoms; this study investigates the incidence and nature of such withdrawal.
- A retrospective review of ICU patients on dexmedetomidine for at least 72 hours found that 35.5% experienced withdrawal symptoms, with rebound hypertension being the most common sign.
- Patients experiencing withdrawal were more likely to require additional medications like β-blockers and clonidine, and to be reinitiated on dexmedetomidine, but the total dosage and duration of the drug were similar between withdrawal and non-withdrawal groups.